Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY: XBI )

87.97 +0.08 (+0.09%)
Official Closing Price Updated: 8:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about SPDR Series Trust SPDR S&P Biotech ETF

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
The Dean Martin, “You’re Nobody ‘Till Somebody Loves You” Stock Market (And Sentiment Results)…
China Tech (Alibaba) and Biotech have been the two least-loved sectors in recent weeks, but we believe this is changing. 
Via Talk Markets
XBI Biotech 15% Potential
The Biotech Sector ETF had a very nice rally, a bull flag, and ended up having the second half of the move to the upside. 
Via Talk Markets
Small Cap Biotech Stocks: Is it time to start trading?
It’s time to trade beaten-up small cap biotech stocks. 
Via Talk Markets
3 Pharma Stocks Yielding Over 3%
The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries. 
Via Talk Markets
9 Monster Stock Market Predictions – The Week Of Jan. 17
The chart for the SPX is looking more and more like a diamond pattern. 
Via Talk Markets
Top 10 Investment Themes For 2022
What are the investment trends going to look like for 2022? 
Via Talk Markets
ETF Battles: Which Biotech Stock ETF Is The Better Choice? - It's IBB Vs. XBI
A biotech clash between the iShares Biotechnology ETF and the SPDR S&P Biotech ETF. 
Via Talk Markets
3 Biotech Stocks to Buy That Are Under Severe Pressure
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom. 
Via InvestorPlace
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
Whitney Tilson Names Cannabis ETF 'Favorite Pick For 2022' But Clock Is Ticking To Change US Regulations
It was another brutal year for cannabis stock investors in 2021 as the U.S. made very little regulatory progress on cannabis reform measures. Fortu... 
Via Benzinga
Fear & Greed In The Biotech Sector
With rates rising, widespread tax-loss selling, and fund manager’s either closing the books for 2021 or just closing down altogether, the market has entered a major risk off phase and biotech stocks... 
Via Talk Markets
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
The Bear Market Is Already Here – But Not For Dividend Investors
While the broad stock market indices remain at near-record levels, there are sectors of the market that have dropped into correction or even bear market territory over recent months. 
Via Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
10 Bargain Stocks to Buy After Falling 30% in 2021
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill. 
Via InvestorPlace
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
8 Monster Stock Market Predictions – The Week Of December 13, 2021 Edition
Via Talk Markets
5 Top-Ranked ETFs to Buy At Bargain Prices
The beaten-down prices have charged up investors to snap up ETFs on the cheap. Investors could definitely look to these products for outsized gains over the longer term. 
Via Talk Markets
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
Tuesday Talk: O(micron) - Pow(ell)!
As Wall St. investors await the market open Tuesday, futures dive on Omicron concerns as well as anticipation surrounding Yellen and Powell's Senate testimony this morning. 
Via Talk Markets
Stocks Rise On November 29 On Predictable Volatility Crush
Stocks jumped on November 29 as volatility came down sharply. 
Via Talk Markets
COVID Is Back Disrupting Markets And Causing More Sector Uncertainty
Just when you were having an enjoyable four day weekend cruising along the interminable bull market COVID is back disrupting trends. Healthcare stocks held up reasonably well .Will there be new respect... 
Via Talk Markets
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
Wednesdays With Wedbush On PreMarket Prep Plus
On the PreMarket Prep Plus "Wednesday’s With Wedbush" segment, Sahak Manuelian, managing director and head of equi... 
Via Benzinga
15 Charts All Traders Should Look At Every Morning
One of the hardest things to do as a day trader is gathering all the necessary information to execute profitable trades. Below are the to... 
Via Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Healthcare Stocks Hit New Highs but Small Caps Lag
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field. 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.